Serco ups profit outlook as it offsets hit from Covid-19 test and trace ending

The firm said it now expects underlying trading profit of around £225 million this year – up £30 million on previous guidance.

Holly Williams
Thursday 26 May 2022 08:09
Serco has hiked its full-year profits outlook as the group said stronger-than-expected trading is helping it offset the hit from the end of the Government’s Covid-19 test and trace programme (PA)
Serco has hiked its full-year profits outlook as the group said stronger-than-expected trading is helping it offset the hit from the end of the Government’s Covid-19 test and trace programme (PA)

Outsourcing giant Serco has hiked its full-year profits outlook as stronger-than-expected trading is helping it offset the hit from the end of the Government’s Covid-19 test and trace programme.

The firm said it now expects underlying trading profit of around £225 million this year – up £30 million on previous guidance and “significantly” better than it feared in February.

It had warned over the impact from the end of test and trace – a loss of £220 million worth of revenues in the first half and £260 million in the second half.

We have had a strong start to the year, and it is pleasing to be able to increase reported profit guidance to levels approaching last year’s

Rupert Soames, Serco group chief executive

But the group said it was now set to replace these lost revenues with increased work on immigration contracts and other government programmes worldwide, which it believes will help annual results approach levels seen in 2021.

Rupert Soames, Serco group chief executive, said: “We have had a strong start to the year, and it is pleasing to be able to increase reported profit guidance to levels approaching last year’s.

“To deliver this outcome, we are having to replace with other work some £500 million of revenues and over £60 million of contract profits from the ending of Test & Trace and of the AWE (Atomic Weapons Establishment) contract.

“We are able to do this because customers rely on us to deliver their critical programmes, and this has driven strong order intake over recent years on contracts that are now delivering revenues and profits.”

The firm is now pencilling revenues for the first half of 2022 of just over over £2 billion.

Full-year revenues are expected to reach £4.3 billion to £4.4 billion, in line with the previous year.

Serco had previously forecast 2022 revenues of between £4.1 billion and £4.2 billion.

The group said in the UK and Europe, it expects turnover to drop by around 5% year-on-year to £1 billion, even after the test and trace blow.

It added it was “well protected” against soaring inflation.

“Although it is hard to forecast the precise impact on revenues and costs, the nature of our contractual arrangements with our customers means we do not expect costs to increase faster than revenues,” Serco added.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in